Skip to content

Clinical trials

Obesity trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Obesity Country / region: China Clear all

560 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20052
20062
20071
20082
20094
20107
201112
20126
20133
201410
20158
201610
201715
201813
201925
202021
202132
202240
202349
202475
2025106
2026114

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed216
Recruiting124
Unknown status93
Not yet recruiting61
Active, not recruiting50
Terminated6
Withdrawn6
Enrolling by invitation4

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Eli Lilly and Company25
Novo Nordisk A/S15
Fujian Shengdi Pharmaceutical Co., Ltd.13
Peking University12
Shanghai Minwei Biotechnology Co., Ltd12
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School12
Innovent Biologics (Suzhou) Co. Ltd.10
Beijing QL Biopharmaceutical Co.,Ltd9
China-Japan Friendship Hospital9
Gan & Lee Pharmaceuticals.9

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Obesity560
Overweight279
Diabetes Mellitus, Type 261
Weight Loss25
Metabolic Syndrome21
Diabetes Mellitus19
Hypertension19
Prediabetic State14
Non-alcoholic Fatty Liver Disease12
Polycystic Ovary Syndrome11

Trials

Showing 51 to 75 of 560. Each trial links to its page on Pharma Observatory.

460 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.